Chordoma

Current Opinion in Oncology

Volumn 19, Issue 4, 2007, Pages 367-370

  Casali, Paolo G ^a   Stacchiotti, Silvia ^a   Sangalli, Claudia ^a   Olmi, Patrizia ^a   Gronchi, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chordoma; Hadron radiation therapy; Imatinib mesylate; Molecular targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; SCATTER FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHORDOMA; HUMAN; PRIORITY JOURNAL; REVIEW; SACRUM; SKULL BASE; SPINE; STATISTICAL SIGNIFICANCE; SYMPTOM;

ANTINEOPLASTIC AGENTS; CHORDOMA; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SACROCOCCYGEAL REGION; SKULL BASE NEOPLASMS; SPINAL NEOPLASMS;

EID: 34250017664     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3281214448     Document Type: Review

References (45)

1. Newton HB. Chordomas. In: Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA, editors. Textbooks of Uncommon Cancer. 3rd ed. Chichester: John Wiley & Sons Ltd; 2006. pp. 614-625.
2. Mirra JM, Della Rocca C, Nelson SD, Mertens F. Chordoma. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002. pp. 316-317.
3. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg 2005; 87-A:2211-2216.
4. Osaka S, Kodoh O, Sugita H, et al. Clinical significance of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin Oncol 2006; 132:213-218.
5. Tzortzidis F, Elahi F, Wright D, et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006; 59:230-237; discussion 230-237. In a total of 74 patients with cranial base chordomas, the 10-year recurrence-free survival was 42% for primarily operated patients, and 26% for reoperated ones. Results are put into perspective against published series on cranial base chordoma.
6. Boriani S, Bandiera S, Biagini R, et al. Chordoma of the mobile spine: fifty years of experience. Spine 2006; 31:493-503. This is a consecutive series of 52 patients with the rarest presentation of chordoma, the mobile spine. En bloc resection with tumor-free margins of previously uncontaminated lesions seems the only surgical option by which a chance of cure can be pursued.
7. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003; 10:291-296.
8. York JE, Kaczaraj A, Abi-Said D, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 1999; 44:74-79; discussion 79-80.
9. Al-Mefty O, Borba LA. Skull base chordomas: a management challenge. J Neurosurg 1997; 86:182-189.
10. Forsyth PA, Cascino TL, Shaw EG, et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993; 78:741-747.
11. Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 1995; 36:887-896; discussion 896-897.
12. Devin C, Chong PY, Holt GE, et al. Level-adjusted perioperative risk of sacral amputations. J Surg Oncol 2006; 94:203-211.
13. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr. Lumbosacral chordoma. Prognostic factors and treatment. Spine 1999; 24:1639-1645.
14. Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000; 88:2122-2134.
15. Tai PT, Craighead P, Bagdon F. Optimization of radiotherapy for patients with cranial chordoma. A review of dose-response ratios for photon techniques. Cancer 1995; 75:749-756.
16. Austin JP, Urie MM, Cardenosa G, Munzenrider JE. Probable causes of recurrence in patients with chordoma and chondrosarcoma of the base of skull and cervical spine. Int J Radiat Oncol Biol Phys 1993; 25:439-444.
17. Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996; 41:67-72.
18. Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9:633-642.
19. Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys 1999; 45:351-358.
20. Suit HD, Goitein M, Munzenrider J, et al. Definitive radiation therapy for chordoma and chondrosarcoma of base of skull and cervical spine. J Neurosurg 1982; 56:377-385.
21. Austin-Seymour M, Munzenrider JE, Goitein M, et al. Progress in low-LET heavy particle therapy: intracranial and paracranial tumors and uveal melanomas. Radiat Res Suppl 1985; 8:S219-S226.
22. Austin-Seymour M, Munzenrider J, Goitein M, et al. Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull. J Neurosurg 1989; 70:13-17.
23. Benk V, Liebsch NJ, Munzenrider JE, et al. Base of skull and cervical spine chordomas in children treated by high-dose irradiation. Int J Radiat Oncol Biol Phys 1995; 31:577-581.
24. Berson AM, Castro JR, Petti P, et al. Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: the Lawrence Berkeley Laboratory experience. Int J Radiat Oncol Biol Phys 1988; 15:559-565.
25. Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999; 91:432-439.
26. Noel G, Feuvret L, Calugaru V, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005; 44:700-708.
27. Schulz-Ertner D, Haberer T, Jakel O, et al. Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int J Radiat Oncol Biol Phys 2002; 53:36-42.
28. Imai R, Kamada T, Tsuji H, et al. Working Group for Bone, Soft Tissue Sarcomas. Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res 2004; 10:5741-5746.
29. Gabriele P, Macias V, Stasi M, et al. Feasibility of intensity-modulated radiation therapy in the treatment of advanced cervical chordoma. Tumori 2003; 89:298-304.
30. Muthukumar N, Kondziolka D, Lunsford LD, Flickinger JC. Stereotactic radiosurgery for chordoma and chondrosarcoma: further experiences. Int J Radiat Oncol Biol Phys 1998; 41:387-392.
31. Debus J, Schulz-Ertner D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 2000; 47:591-596.
32. Feigl GC, Bundschuh O, Gharabaghi A, et al. Evaluation of a new concept for the management of skull base chordomas and chondrosarcomas. J Neurosurg 2005; 102:165-170.
33. Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Treatment planning intercomparison for spinal chordomas using intensity-modulated photon radiation therapy (IMRT) and carbon ions. Phys Med Biol 2003; 48: 2617-2631.
34. Rutz HP, Weber DC, Sugahara S, et al. Extracranial chordoma: Outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int J Radiat Oncol Biol Phys 2007; 67:512-520.
35. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006; 65:1514-1521. In 27 patients with sacral chordoma treated with proton and photon beam radiation therapy alone or combined with surgery, a high local control was achieved in those with a primary tumor as compared with recurrences, including a few patients treated with high-dose radiation therapy alone. Results are put into perspective against published series of sacral chordomas treated with radiation and/or surgical treatment, with a view to current policies and the ongoing innovative approaches.
36. Rhomberg W, Eiter H, Bohler F, Dertinger S. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas. Anticancer Res 2006; 26:2407-2411.
37. Fleming GF, Heimann PS, Stephens JK, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993; 72:714-718.
38. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004; 101:2086-2097.
39. Casali PG, Stacchiotti S, Messina A, et al. Imatinib mesylate in 18 advanced chordoma patients [abstract]. J Clin Oncol 2005; 23 (suppl):9012.
40. Tamborini E, Miselli F, Negri T, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006; 12:6920-6928. In 31 tumor samples of chordoma, PDGF receptor β was highly expressed and phosphorylated, and PDGF receptor α and KIT were less expressed but phosphorylated, in the lack of any activating mutation, thus suggesting an autocrine/ paracrine loop. This is likely the basis for imatinib's antitumor activity in the disease.
41. Burger H, den Bakker MA, Kros JM, et al. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005; 4:1270-1274.
42. Schonegger K, Gelpi E, Prayer D, et al. Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs 2005; 16:1139-1143.
43. Weinberger PM, Yu Z, Kowalski D, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 2005; 131:707-711.
44. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006; 29:572-574. This case report shows a tumor response to the combination of cetuximab and gefitinib in an advanced chordoma patient, thus suggesting the possibility that targeting EGFR may result in antitumor activity, following previous demonstration about targeting PDGF receptor.
45. Stacchiotti S, Grosso F, Dileo P, et al. Antitumor activity of imatinib plus cisplatin in two patients with advanced chordoma [abstract #725]. Proc. 12th Annual Connective Tissue Oncology Society Meeting, 2006. p. 58.